Collegium Pharmaceutical Inc. ( (COLL) ) has released its Q1 earnings. Here is a breakdown of the information Collegium Pharmaceutical Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Collegium Pharmaceutical, Inc. is a biopharmaceutical company focused on developing and commercializing innovative medicines for pain management and neuropsychiatry, with a notable presence in the ADHD treatment market through its product, Jornay PM.
In its first quarter of 2025, Collegium Pharmaceutical reported a significant 23% increase in net revenue year-over-year, reaching $177.8 million. The company highlighted strong growth in its ADHD product, Jornay PM, and its pain management portfolio, alongside strategic expansions and financial initiatives.
Key financial highlights include a 24% year-over-year increase in Jornay PM prescriptions, generating $28.5 million in quarterly net revenue. The pain portfolio also saw a 3% revenue increase, with all three core products contributing to this growth. The company ended the quarter with $197.8 million in cash and marketable securities and announced a $25 million accelerated share repurchase program.
Collegium’s management remains optimistic about the future, reaffirming their full-year 2025 financial guidance. They anticipate continued growth driven by strategic investments in Jornay PM and the pain portfolio, alongside disciplined capital deployment to enhance shareholder value.